Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Meningioma 1

Interventions

pembrolizumab 31Carboplatin 24Specimen Handling 19Magnetic Resonance Spectroscopy 17Cyclophosphamide 17Nivolumab 14Dexamethasone 14Bevacizumab 13fludarabine 12atezolizumab 11Temozolomide 11Gemcitabine 11Biopsy 11Paclitaxel 10venetoclax 9Pemetrexed 9Ipilimumab 9Cisplatin 8Rituximab 7Prednisone 7Oxaliplatin 7Lenalidomide 7Fluorouracil 7Docetaxel 7Capecitabine 7olaparib 6Vincristine 6Leucovorin 6patritumab deruxtecan 5lenvatinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ga(III)-DOTATOC × 30 days × Clear all
NCT07150806 2026-05-22

RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Recruiting
30 enrolled
CNS

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡